87.90
Dexcom Inc stock is traded at $87.90, with a volume of 2.27M.
It is down -2.02% in the last 24 hours and up +1.10% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$89.71
Open:
$88.78
24h Volume:
2.27M
Relative Volume:
0.47
Market Cap:
$33.17B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
37.59
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
-3.22%
1M Performance:
+1.10%
6M Performance:
+20.58%
1Y Performance:
+8.84%
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DXCM
Dexcom Inc
|
87.90 | 34.05B | 4.82B | 930.40M | 1.43B | 2.3381 |
|
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Law firm probes DexCom officers for possible br... - Pluang
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Dexcom Inc. stock holds near consensus target on solid Q2 2026 growth - AD HOC NEWS
Dexcom stock holds near USD 89.71 after strong Q2 - AD HOC NEWS
DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair - finance.yahoo.com
Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks - finance.yahoo.com
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services - Barron's
ETFs Investing in DexCom, Inc. Stocks - TradingView
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Eastern Progress
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
3 Reasons DXCM Has Explosive Upside Potential - Yahoo Finance
Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today - qz.com
Dexcom Announces Upcoming Conference Presentation - Business Wire
G7 Momentum and Global Reach Might Change The Case For Investing In DexCom (DXCM) - simplywall.st
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings And A Promising 3.63% Upside - DirectorsTalk Interviews
Dexcom (DXCM) HR chief cashes out 2,565 company shares - stocktitan.net
Dexcom Defeats Investor Suit Over Glucose Monitor Market Share - Bloomberg Law News
DexCom (NASDAQ: DXCM) officer may sell 2,565 shares on Aug. 27, 2026 - Stock Titan
We Ran A Stock Scan For Earnings Growth And DexCom (NASDAQ:DXCM) Passed With Ease - Moomoo
Dexcom (NASDAQ: DXCM) officer keeps 101,502 shares after tax withholding - Stock Titan
Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now? - Eastern Progress
Dexcom (NASDAQ: DXCM) chair sells 26,756 shares around $90 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) - The National Law Review
DexCom (NASDAQ:DXCM) Reaches New 52-Week HighStill a Buy? - MarketBeat
DexCom stock hits 52-week high at 91.99 USD - Investing.com
DexCom Study Demonstrates CGM Benefits in Type 2 Diabetes - Medical Product Outsourcing
DXCM Shareholders Have Opportunity to Lead DexCom, Inc. Class Act - The National Law Review
DexCom posts $1.31B quarter as Silvant Capital opens a $5.4M stake - Dealroom
Silvant Capital Management LLC Takes $5.36 Million Position in DexCom, Inc. $DXCM - MarketBeat
Trillium Asset Management LLC Invests $3.23 Million in DexCom, Inc. $DXCM - MarketBeat
Danske Bank A S Purchases New Holdings in DexCom, Inc. $DXCM - MarketBeat
Dexcom (NASDAQ:DXCM) Combines Strong Growth With a Bullish Technical Setup - ChartMill
Dexcom stock holds close to analyst target as growth story stays intact - Ad-hoc-news.de
E Fund Management Co. Ltd. Acquires New Holdings in DexCom, Inc. $DXCM - MarketBeat
Edmond DE Rothschild Holding S.A. Invests $5.01 Million in DexCom, Inc. $DXCM - MarketBeat
Deutsche Bank AG Takes Position in DexCom, Inc. $DXCM - MarketBeat
Aurora Investment Counsel Invests $2.34 Million in DexCom, Inc. $DXCM - MarketBeat
Dexcom (NASDAQ: DXCM) Kevin R. Sayer plans multimillion-dollar stock sale - Stock Titan
Mitsubishi UFJ Asset Management Co. Ltd. Takes Position in DexCom, Inc. $DXCM - MarketBeat
12,080 Shares in DexCom, Inc. $DXCM Bought by Alamar Capital Management LLC - MarketBeat
Dexcom stock edges higher as Q1 2026 growth and CGM demand support valuation - Ad-hoc-news.de
Flputnam Investment Management Co. Makes New Investment in DexCom, Inc. $DXCM - insurancenewsnet.com
Performance Wealth Partners LLC Takes Position in DexCom, Inc. $DXCM - MarketBeat
GSA Capital Partners LLP Takes $1.33 Million Position in DexCom, Inc. $DXCM - MarketBeat
Global Retirement Partners LLC Purchases Shares of 20,784 DexCom, Inc. $DXCM - MarketBeat
Provident Investment Management, Inc.'s DexCom Inc(DXCM) Holding History - GuruFocus
DexCom (DXCM) Stock May Trade At A 37% Discount On Cash Flow - Yahoo Finance
DexCom Inc (MIL:1DXCM) Stock Price, Trades & News - GuruFocus
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) legal chief sells stock under 10b5-1 plan - Stock Titan
DexCom (DXCM) Rebounds On Growth Hopes, Does It Look Fully Valued? - Yahoo Finance
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):